Top 10 ASX Dividend Stocks for Nov 2026 Download Free Report

1800-272-662
Shopping Cart 0
countryflagAU
Login

Home CompaniesCeryvyn Therapeutics Limited

Ceryvyn Therapeutics Limited

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.009 AUD -0.00 ( 10.00%)
Last update at 2026-11-12T04:57:00Z
VOLUME
3054766
Market Cap
13.68M
P/E
0.04

Momentum Score

…

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.01
Low
0.01
High
52 Week Price Range
0.01
Low
0.60
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Ceryvyn Therapeutics Limited is an Australian-listed company operating in the therapeutics/biotechnology sector; public disclosures provide limited detail about its specific programs and commercial activities. Long-term growth may depend on progress in any clinical or preclinical programs, successful regulatory outcomes, licensing or commercialization deals, and the company’s ability to secure additional capital, which could support value creation if development milestones are met.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.01
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-
ROE
-
Net Debt
-
ROCE
-40.34%
Diluted EPS TTM
0.24

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Income before tax 330.24M -169.74M -229.65M -148.45M -99.12M
Net income 330.44M -162.79M -220.24M -142.52M -92.82M
Selling general administrative 8.04M 20.54M 12.77M 12.78M 13.59M
Gross profit - - - -0.06M -0.04M
Reconciled depreciation 0.00M 0.09M 0.10M 0.10M 0.08M
Operating income -11.95M -152.31M -191.84M -150.03M -96.54M
Interest expense 11.06M 46.46M 30.26M 13.46M 0.00M
Tax provision -0.21M -6.95M -9.41M -5.93M -6.30M
Interest income 1.04M 5.53M 3.40M 3.23M 0.24M
Net interest income -10.02M -40.92M -26.87M -10.23M 0.24M
Total revenue 0.00M 0.03M 0.12M 0.11M 0.09M
Total operating expenses 11.95M 152.34M 191.97M 150.13M 96.63M
Cost of revenue - - - 0.17M 0.13M
Total other income expense net 352.20M 23.50M -10.94M 11.81M -2.81M
Net income from continuing ops 330.44M -162.79M -220.24M -142.52M -92.82M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Total assets 31.93M 56.80M 188.79M 98.64M 60.05M
Total liab 2.32M 257.87M 264.60M 104.49M 12.07M
Total stockholder equity 29.61M -201.07M -75.81M -5.85M 47.98M
Other current liab - 246.99M 24.84M - -
Capital stock 732.47M 497.49M 466.08M 320.88M 235.28M
Retained earnings -759.61M -742.50M -579.70M -359.46M -216.94M
Cash 30.02M 48.44M 172.47M 89.19M 44.63M
Total current liabilities 2.32M 257.87M 64.06M 18.74M 12.04M
Total current assets 31.93M 56.80M 188.19M 98.39M 59.91M
Long term debt - - 141.55M 85.66M -
Accounts payable 2.32M 9.74M 38.06M 17.84M 11.40M
Non current assets total 0.00M 0.00M 0.60M 0.26M 0.14M
Capital lease obligations - 0.00M 0.09M 0.18M 0.00M
Breakdown 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Type yearly yearly yearly yearly yearly
Date 2026-06-30 2025-06-30 2024-06-30 2023-06-30 2022-06-30
Investments - - - - 0.00M
Net borrowings 0.00M -0.09M -0.09M -0.07M -0.09M
Total cash from financing activities -30.89M 34.77M 243.73M 167.28M 0.17M
Net income 330.44M -162.79M -324.31M -219.45M -134.52M
Change in cash -43.38M -123.89M 82.68M 46.66M -71.18M
Begin period cash flow 73.94M 172.47M 89.19M 44.63M 118.19M
End period cash flow 30.02M 48.44M 172.47M 89.19M 44.63M
Total cash from operating activities - - -161.02M -120.61M -71.33M
Issuance of capital stock 0.00M 34.81M 158.82M 81.81M 0.00M
Depreciation - - 0.10M 0.10M 0.08M
Capital expenditures 0.00M 0.01M 0.03M 0.02M 0.02M
Change in working capital - - 17.30M 13.95M 14.66M
Stock based compensation - - 5.08M 5.83M 5.25M
Other non cash items - - 41.49M 13.46M -
Free cash flow -12.50M -158.66M -161.05M -120.63M -71.35M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(AUD)
Price
(AUD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CYV
Ceryvyn Therapeutics Limited		 -0.00
10.00%		 0.01 0.04 6.75 13679.78 0.46 54416.08 0.16
CSL
CSL Ltd		 2.86
1.42%		 204.54 - 22.57 6.15 4.48 4.82 10.06
TLX
TELIX Pharmaceuticals Ltd		 -0.32
2.28%		 13.70 93.87 166.67 5.37 6.37 3.85 47.29
NEU
Neuren Pharmaceuticals Ltd		 -0.30
1.25%		 23.66 154.93 36.36 42.38 7.52 31.95 160.40
MSB
Mesoblast Ltd		 -0.07
3.69%		 1.96 - 454.55 23.43 3.36 18.28 -9.86

Profile*

Ceryvyn Therapeutics Limited

Ceryvyn Therapeutics Limited, a biopharmaceutical company, develops biologic therapy for the rare disease lymphangioleiomyomatosis in Australia. The company offers CYV-101, which is in pre-clinical trial stage, an inhaled therapy intended for delivery directly to the lung. It serves the biotechnology and healthcare industries. The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. Ceryvyn Therapeutics Limited was incorporated in 1984 and is headquartered in Hawthorn East, Australia.

117 Camberwell Road, Hawthorn East, VIC, Australia, 3123

61 3 9826 0399

https://ceryvyn.com

Name Title Year Born
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. CEO & Chairperson 1953
Mr. Hamish George CFO & Joint Company Secretary NA
Dr. Stuart Mudge Chief Operating Officer NA
Dr. Michael Gerometta Ph.D. Chief Technology Officer 1965
Ms. Stephanie Vipond Joint Company Secretary NA
Ms. Rebbecca Wilcox Senior VP of Preclinical and Translational Science NA
Dr. Jeremy Max Levin Ba Zoology, Dphil, M.D., Mb Bchir, Ph.D. Executive Chair & CEO 1953
Dr. Michael Gerometta Ph.D. Chief Technology Officer 1964

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

CU6
AUD 2.05
+23.49%
DMP
AUD 25.06
+12.93%
G6M
AUD 2.74
+10.93%
XRO
AUD 75.17
+6.08%
SGR
AUD 0.17
+6.06%
AXQ
AUD 3.07
-18.35%
BOE
AUD 1.50
-9.39%
GQG
AUD 0.71
-8.97%
MI6
AUD 0.81
-8.52%
ELV
AUD 3.73
-8.35%

Equity Sectors*

  • Basic Materials

    -3.09%

  • Communication Services

    +0.75%

  • Consumer Cyclical

    +0.43%

  • Consumer Defensive

    +0.12%

  • Energy

    -1.07%

  • Financial Services

    -0.02%

  • Healthcare

    +1.08%

  • Industrials

    -0.22%

  • Real Estate

    +0.61%

  • Technology

    -1.69%

  • Utilities

    -0.18%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…